Canadian Phase Onward | Toronto, Canada
Status and phase
Conditions
Treatments
About
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,280 participants in 1 patient group
Loading...
Central trial contact
Ron Farkas, MD; Luigi Taranto, MD, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal